Regenerex Pharma, Inc. (OTC: RGPX), a company focused on advanced wound closure systems, has formed a partnership with Holista Colltech Ltd. of Perth, Australia. The agreement centers on the exclusive supply and development of wound care products.
Under the terms of the agreement, Holista Colltech will be the sole supplier of its ovine collagen to Regenerex. This includes their patented 300 kDa intact collagen and nano-collagen technologies. The initial market focus will be the United States, with plans for global expansion.
Regenerex will have exclusive worldwide rights to market Holista‘s collagen for wound care applications. The agreement includes minimum purchase commitments for Regenerex, starting at $50,000 in 2025 and increasing significantly in subsequent years.
Regenerex will be responsible for funding and conducting clinical studies and obtaining necessary regulatory approvals, including those from the U.S. FDA. Both companies will jointly collaborate on the development of new nano-collagen applications in wound care, sharing any resulting intellectual property.
Holista‘s ovine collagen will be sourced from its Collie (WA) manufacturing facility, with nano-collagen production taking place in Malaysia. Both facilities operate under international Good Manufacturing Practice (GMP) and halal certification standards.
The agreement’s duration is tied to the lifespan of relevant patents. However, the agreement can be terminated early under certain conditions, including after 90 days’ notice or due to breach of contract, insolvency, or mutual agreement.
Regenerex aims to provide innovative solutions for chronic wound closure and reduce amputations. Their products are designed to treat various wound types, including diabetic foot ulcers, venous ulcers, burns, and pressure ulcers. The company claims high success rates in healing chronic wounds.
Holista Colltech is a major producer of high-purity ovine collagen, utilizing Australia‘s stringent biosecurity standards and ethical sourcing practices. They are dedicated to creating sustainable health innovations using premium natural ingredients for both medical and consumer uses.
The companies anticipate that this collaboration will lead to the development and commercialization of advanced wound care products that improve patient outcomes. The financial impact on both companies remains to be seen, but the partnership signals a significant step forward in the wound care market. The agreement’s success hinges on the successful completion of clinical trials and securing regulatory approvals.
Related
